ReviewCureus2026
Comprehensive Molecular Profiling for Precision Diagnostics: Integrating Genomic, Proteomic, and Epigenetic Landscapes in Human Pathology.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comprehensive molecular characterization may enhance diagnostic assessment in complex human diseases by capturing biological heterogeneity beyond conventional single-layer approaches. This review examines the integration of genomic, proteomic, and epigenetic profiling for precision diagnostics and clinical interpretation. Major advances include comprehensive genomic characterization, high-throughput proteomic profiling, clinically informative epigenetic biomarkers, machine-learning-assisted data integration, and single-cell and spatial multiomics for resolving cellular and tissue-level heterogeneity. Evidence across diverse disease models indicates that integrated molecular data may enhance biomarker identification and provide additional information for disease classification, prognostic assessment, and prediction of therapeutic response; however, comparative measures of diagnostic performance are not consistently available. Proteomic and epigenetic information provides functional and regulatory context to genomic alterations, enabling a more complete representation of disease mechanisms. Current barriers include heterogeneous data formats, batch effects, missing data, limited standardization, high computational and financial requirements, privacy and regulatory concerns, and insufficient clinical validation. Future priorities should focus on harmonized analytical standards, reproducible pipelines, scalable computational infrastructure, improved model interpretability, robust clinical validation, and stronger interdisciplinary collaboration across oncology, rare genetic disorders, neurodegenerative disease, and other clinically heterogeneous conditions in routine practice. Integrative molecular profiling therefore represents a major direction for next-generation diagnostics, with its potential clinical value depending on analytical validation, clinical validity and utility, reproducible implementation, and prospective comparison with established diagnostic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.